WEKO3
アイテム
{"_buckets": {"deposit": "5fd75d19-44e9-48a9-a620-ef0c7eefa55e"}, "_deposit": {"created_by": 1, "id": "72766", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "72766"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00072766", "sets": ["28"]}, "author_link": ["716776", "716770", "716775", "716778", "716768", "716771", "716769", "716773", "716767", "716777", "716774", "716772"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2018-04-23", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background / Aims: We have developed meta-[211At]astato-benzylguanidine (MABG) for targeted alpha-radionuclide therapy of malignant pheochromocytoma and shown its high antitumor effects in tumor-bearing mice. However, body weight loss, an indicator of toxicity, was transiently observed at therapeutic dose. In this study, we investigated for alleviation of toxicity whether non-specific uptake of MABG could be reduced by inhibiting organic cation transporter (OCT). \nMethods: The uptake of MABG was examined using the following cell lines, PC-12, rat pheochromocytoma, HT-29, human colorectal adenocarcinoma, ACHN, human renal cell adenocarcinoma, BxPC-3, human pancreatic adenocarcinoma. To inhibit OCT, cells were treated with phenoxybenzamine (POB), an inhibitor of OCT1-3, ranitidine (RAN), an inhibitor of OCT1, or hydrocortisone (HDC), an inhibitor of OCT3. \nResults: POB (3 μM), RAN (100 μM) and HDC (10 μM) significantly reduced the uptake of MABG in HT-29, ACHN and BxPC-3. While, the uptake of MABG in PC-12 was slightly inhibited by treatment with POB, but not RAN and HDC. These results indicate that OCT1 and OCT3 were involved in the uptake of MABG in HT-29, ACHN and BxPC-3, but not in PC-12. Therefore, RAN or HDC possibly inhibit the non-specific uptake of MABG in colon, kidney and pancreas. Dose-response study showed that the inhibitory effect of RAN and HDC in HT-29, ACHN and BxPC-3 was enhanced dose-dependently. However, high-dose of RAN (1000 μM), but not HDC (100 μM), reduced the uptake of MABG in PC-12. These results suggest that HDC can inhibit the nonspecific uptake of MABG more selectively.\nConclusion: Our results showed that the non-specific uptake of MABG is possibly reduced by inhibiting OCT1 and OCT3. Furthermore, HDC is a clinically approved drug, and can be a selective inhibitor for reducing non-specific uptake of MABG. At present, we are investigating the usefulness of HDC in tumor-bearing mice.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "12th World Congress of The World Federation of Nuclear Medicine and Biology (WFNMB2018)", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "大島, 康宏"}], "nameIdentifiers": [{"nameIdentifier": "716767", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺, 茂樹"}], "nameIdentifiers": [{"nameIdentifier": "716768", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下, 哲哉"}], "nameIdentifiers": [{"nameIdentifier": "716769", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐々木, 一郎"}], "nameIdentifiers": [{"nameIdentifier": "716770", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東, 達也"}], "nameIdentifiers": [{"nameIdentifier": "716771", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡, 典子"}], "nameIdentifiers": [{"nameIdentifier": "716772", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大島 康宏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716773", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺 茂樹", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716774", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下 哲哉", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716775", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐々木 一郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716776", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東 達也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716777", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡 典子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "716778", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Inhibition of organic cation transporter reduces non-specific uptake of MABG", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Inhibition of organic cation transporter reduces non-specific uptake of MABG"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/72766", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-05-01"}, "publish_date": "2018-05-01", "publish_status": "0", "recid": "72766", "relation": {}, "relation_version_is_last": true, "title": ["Inhibition of organic cation transporter reduces non-specific uptake of MABG"], "weko_shared_id": -1}
Inhibition of organic cation transporter reduces non-specific uptake of MABG
https://repo.qst.go.jp/records/72766
https://repo.qst.go.jp/records/72766663b6e47-256c-4fb3-a8af-85eaa9860b19
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-05-01 | |||||
タイトル | ||||||
タイトル | Inhibition of organic cation transporter reduces non-specific uptake of MABG | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
大島, 康宏
× 大島, 康宏× 渡辺, 茂樹× 坂下, 哲哉× 佐々木, 一郎× 東, 達也× 石岡, 典子× 大島 康宏× 渡辺 茂樹× 坂下 哲哉× 佐々木 一郎× 東 達也× 石岡 典子 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background / Aims: We have developed meta-[211At]astato-benzylguanidine (MABG) for targeted alpha-radionuclide therapy of malignant pheochromocytoma and shown its high antitumor effects in tumor-bearing mice. However, body weight loss, an indicator of toxicity, was transiently observed at therapeutic dose. In this study, we investigated for alleviation of toxicity whether non-specific uptake of MABG could be reduced by inhibiting organic cation transporter (OCT). Methods: The uptake of MABG was examined using the following cell lines, PC-12, rat pheochromocytoma, HT-29, human colorectal adenocarcinoma, ACHN, human renal cell adenocarcinoma, BxPC-3, human pancreatic adenocarcinoma. To inhibit OCT, cells were treated with phenoxybenzamine (POB), an inhibitor of OCT1-3, ranitidine (RAN), an inhibitor of OCT1, or hydrocortisone (HDC), an inhibitor of OCT3. Results: POB (3 μM), RAN (100 μM) and HDC (10 μM) significantly reduced the uptake of MABG in HT-29, ACHN and BxPC-3. While, the uptake of MABG in PC-12 was slightly inhibited by treatment with POB, but not RAN and HDC. These results indicate that OCT1 and OCT3 were involved in the uptake of MABG in HT-29, ACHN and BxPC-3, but not in PC-12. Therefore, RAN or HDC possibly inhibit the non-specific uptake of MABG in colon, kidney and pancreas. Dose-response study showed that the inhibitory effect of RAN and HDC in HT-29, ACHN and BxPC-3 was enhanced dose-dependently. However, high-dose of RAN (1000 μM), but not HDC (100 μM), reduced the uptake of MABG in PC-12. These results suggest that HDC can inhibit the nonspecific uptake of MABG more selectively. Conclusion: Our results showed that the non-specific uptake of MABG is possibly reduced by inhibiting OCT1 and OCT3. Furthermore, HDC is a clinically approved drug, and can be a selective inhibitor for reducing non-specific uptake of MABG. At present, we are investigating the usefulness of HDC in tumor-bearing mice. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 12th World Congress of The World Federation of Nuclear Medicine and Biology (WFNMB2018) | |||||
発表年月日 | ||||||
日付 | 2018-04-23 | |||||
日付タイプ | Issued |